Author Correction: Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer

• Paolo Tarantino,
• Hersh Gupta,
• Melissa E. Hughes,
• Janet Files,
• Sarah Strauss,
• Gregory Kirkner,
• Anne-Marie Feeney,
• Yvonne Li,
• Ana C. Garrido-Castro,
• Romualdo Barroso-Sousa,
• Brittany L. Bychkovsky,
• Simona DiLascio,
• Lynette Sholl,
• Laura MacConaill,
• Neal Lindeman,
• Bruce E. Johnson,
• Matthew Meyerson,
• Rinath Jeselsohn,
• Xintao Qiu,
• Rong Li,
• Henry Long,
• Eric P. Winer,
• Deborah Dillon,
• Giuseppe Curigliano,
• Andrew D. Cherniack,
• Sara M. Tolaney,
• Nancy U. Lin

Affiliations

Paolo Tarantino

Medical Oncology, Dana-Farber Cancer Institute

Hersh Gupta

Medical Oncology, Dana-Farber Cancer Institute

Melissa E. Hughes

Medical Oncology, Dana-Farber Cancer Institute

Janet Files

Medical Oncology, Dana-Farber Cancer Institute

Sarah Strauss

Medical Oncology, Dana-Farber Cancer Institute

Gregory Kirkner

Medical Oncology, Dana-Farber Cancer Institute

Anne-Marie Feeney

Medical Oncology, Dana-Farber Cancer Institute

Yvonne Li

Medical Oncology, Dana-Farber Cancer Institute

Ana C. Garrido-Castro

Medical Oncology, Dana-Farber Cancer Institute

Romualdo Barroso-Sousa

Dasa Institute for Education and Research (IEPD)

Brittany L. Bychkovsky

Breast Oncology Program, Dana-Farber Brigham Cancer Center

Simona DiLascio

Medical Oncology, Dana-Farber Cancer Institute

Lynette Sholl

Medical Oncology, Dana-Farber Cancer Institute

Laura MacConaill

Medical Oncology, Dana-Farber Cancer Institute

Neal Lindeman

Medical Oncology, Dana-Farber Cancer Institute

Bruce E. Johnson

Medical Oncology, Dana-Farber Cancer Institute

Matthew Meyerson

Medical Oncology, Dana-Farber Cancer Institute

Rinath Jeselsohn

Medical Oncology, Dana-Farber Cancer Institute

Xintao Qiu

Medical Oncology, Dana-Farber Cancer Institute

Rong Li

Medical Oncology, Dana-Farber Cancer Institute

Henry Long

Medical Oncology, Dana-Farber Cancer Institute

Eric P. Winer

Yale Cancer Center, Yale School of Medicine, Smilow Cancer Hospital

Deborah Dillon

Harvard Medical School

Giuseppe Curigliano

Division of Early Drug Development, European Institute of Oncology IRCCS

Andrew D. Cherniack

Medical Oncology, Dana-Farber Cancer Institute

Sara M. Tolaney

Medical Oncology, Dana-Farber Cancer Institute

Nancy U. Lin

Medical Oncology, Dana-Farber Cancer Institute